Related Experiment Videos
Hexamethylmelamine and pentamethylmelamine: an update.
Drug Intelligence & Clinical Pharmacy
|June 1, 1983
Summary
Hexamethylmelamine (HMM) shows limited efficacy in ovarian and lung cancers due to toxicity. Pentamethylmelamine (PMM) also presents severe side effects, suggesting minimal advantage over HMM.
Area of Science:
- Oncology
- Pharmacology
Background:
- Hexamethylmelamine (HMM) and pentamethylmelamine (PMM) are anticancer agents.
- Toxicity has limited the clinical application of HMM, particularly in ovarian cancer treatment.
Purpose of the Study:
- To review the current status and future prospects of HMM and PMM in cancer therapy.
- To evaluate the efficacy and toxicity profiles of these agents in various cancer types.
Main Methods:
- Review of existing clinical trial data and literature on HMM and PMM.
- Analysis of response rates, survival data, and toxicity profiles.
Main Results:
- HMM combinations in advanced ovarian cancer show moderate response rates with limited impact on survival.
- HMM is being investigated in previously untreated patients and in lung cancer regimens, but its value remains uncertain.
- Pentamethylmelamine (PMM) exhibits severe dose-limiting gastrointestinal and central nervous system toxicities in Phase I studies, indicating limited advantage over HMM.
Conclusions:
- HMM's role in ovarian and lung cancer treatment requires further investigation.
- Future trials are recommended for HMM in endometrial and prostatic carcinomas.
- PMM's therapeutic potential is questionable due to significant toxicity; further dose-schedule studies are needed before advancing to Phase II trials.